Vanina G. Rodriguez

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Improving Long-Term Monitoring in NMIBC: Digital Uromonitor® (dUM) as a Complementary Tool to Cystoscopy for Two-Year Recurrence Risk Stratification.

Improving Long-Term Monitoring in NMIBC: Digital Uromonitor® (dUM) as a Complementary Tool to Cystoscopy for Two-Year Recurrence Risk Stratification.

Journal: Actas urologicas espanolas

Published: February 02, 2026

Capillary constrictions prime cancer cell tumorigenicity through PIEZO1.

Capillary constrictions prime cancer cell tumorigenicity through PIEZO1.

Journal: Nature communications

Published: November 19, 2024

The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma.

The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma.

Journal: Leukemia

Published: August 18, 2020

Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.

Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 22, 2019

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.

Journal: Haematologica

Published: November 13, 2018

Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions.

Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions.

Journal: Molecular therapy. Methods & clinical development

Published: August 31, 2018

Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.

Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.

Journal: International journal of cancer

Published: May 09, 2018

Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma.

Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: November 27, 2017

Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.

Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.

Journal: Haematologica

Published: September 08, 2017

The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.

The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.

Journal: Haematologica

Published: August 26, 2017

Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells.

Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells.

Journal: Scientific reports

Published: May 15, 2017

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling.

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling.

Journal: Haematologica

Published: January 20, 2017

Showing 1-12 of 16

Last Updated: 09/26/2026